Perspective Therapeutics (CATX) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NeOnc Technologies (NTHI) has outperformed Perspective Therapeutics (CATX) over the past year, losing 46.2% versus a loss of 63.9%. Perspective Therapeutics is the larger company by market cap ($91.0 million vs $90.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | NTHI |
|---|---|---|
| Share price | $0.7538 | $3.15 |
| Market cap | $91.03M | $90.88M |
| 1-day change | -3.85% | -9.48% |
| YTD return | -72.59% | -61.91% |
| 1-year return | -63.93% | -46.25% |
| 5-year return | -84.62% | — |
| EPS (TTM) | $-1.25 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $39.99K |
| Revenue growth (YoY) | — | -51.82% |
| Net income (latest FY) | $-103.12M | $-62.15M |
| Operating margin | — | -145637.52% |
| Net margin | — | -155404.38% |
| 52-week high | $6.16 | $11.38 |
| 52-week low | $0.73 | $2.50 |
| Distance from 52-week high | -87.76% | -72.31% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1188.14% | +439.68% |
| Average volume | 2.70M | 187.23K |
| Shares outstanding | 120.76M | 28.85M |
| Employees | 163 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTHI has outperformed CATX by 17.7 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CATX vs NTHI FAQ
Which is bigger, Perspective Therapeutics or NeOnc Technologies?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $91.03M compared with $90.88M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, CATX or NTHI?
NTHI returned -46.25% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.